2018 Influenza Kit - the kits are in the process of being distributed. The envelope clearly states 'ENCLOSED new funded shingles vaccine information leaflet & 2018 Influenza Kit'. If your organisation receives a kit for the attention of a person that is no longer or not associated with your organisation, please retain the information enclosed for your use.
References for 2018 Influenza Kit
2018 Vaccine Order Form
Two funded quadrivalent influenza vaccines for 2018:
For adults and children aged 3 years or older. This vaccine is expected to be available in early-April
For children aged under 3 years, i.e. 6–35 months. This vaccine is expected to be available in mid-April
Of the four influenza strains included in the vaccine, two are new (in bold):
• A/Michigan/45/2015 (H1N1) pdm09- like virus
• A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus
• B/Phuket/3073/2013-like virus
• B/Brisbane/60/2008-like virus
Minimum order requirements
The total influenza vaccine order must meet minimum quantities as follows:
|Min 60 doses
||Min 60 doses
||Min 60 doses
||Min 30 doses
||Min 20 doses
||Min 10 doses
New influenza vaccination precaution
Influenza vaccination may be contraindicated or need to be delayed for people receiving some new cancer treatments. The immune-stimulant actions of:
- atezolizumab (Tecentriq®),
- ipilimumab (Yervoy®),
- nivolumab (Opdivo®)
- pembrolizumab (Keytruda®)
on the immune system increase a person’s risk of developing autoimmune conditions.
It is not known whether receipt of an influenza vaccine whilst receiving these treatments or for up to six months after treatment increases a theoretical risk of triggering the
occurrence of these side effects.
Please contact the person’s oncologist or 0800 IMMUNE (0800 466 863) for current advice about influenza vaccination for these people BEFORE administering the vaccine.
(page 2 in the Flu kit)
INFLUVAC® TETRA and FLUARIX® TETRA can be given to people with egg allergy or anaphylaxis (page 2 in the Flu kit)